332 related articles for article (PubMed ID: 28654672)
1. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
Vissers DC; Lenre M; Tolley K; Jakobsson J; Sendersky V; Jansen JP
Value Health; 2011; 14(2):274-81. PubMed ID: 21402296
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
Ruggeri M; Turriziani A; Oradei M
Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):459-64. PubMed ID: 24702061
[TBL] [Abstract][Full Text] [Related]
4. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
Giuliani J; Fiorica F; Sacchetto A; Franceschini G; Vaccari F; Bonetti A
J Oncol Pharm Pract; 2021 Mar; 27(2):445-447. PubMed ID: 33356990
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
10. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Überall MA
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Romualdi P; Candeletti S
Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough cancer pain in 2020.
Løhre ET; Thronæs M; Klepstad P
Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210
[TBL] [Abstract][Full Text] [Related]
13. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
14. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
[TBL] [Abstract][Full Text] [Related]
16. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
[TBL] [Abstract][Full Text] [Related]
17. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Alberts DS; Smith CC; Parikh N; Rauck RL
Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
20. Use of oral formulations of fentanyl for breakthrough cancer pain.
Handsaker S; Dempsey L; Fabby C
Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
